$0.03
(Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
10 Years Aggregate
CFO
$-178.50 Mln
EBITDA
$-190.49 Mln
Net Profit
$-216.81 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Imunon Inc (IMNN)
| -57.2 | 1.9 | -25.2 | -72.5 | -53.8 | -34.4 | -20.6 |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Imunon Inc (IMNN)
| -69.3 | 39.3 | -49.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Imunon Inc (IMNN)
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the... localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey. Read more
-
Executive Chairman
Mr. Michael H. Tardugno
-
Executive Chairman
Mr. Michael H. Tardugno
-
Headquarters
Lawrenceville, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Imunon Inc (IMNN)
What is the current share price of Imunon Inc (IMNN) Today?
The share price of Imunon Inc (IMNN) is $1.63 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Imunon Inc (IMNN) has given a return of -53.83% in the last 3 years.
What is the current PB & PE ratio of Imunon Inc (IMNN)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.56 |
1.15 |
2024 |
-0.06 |
0.25 |
2023 |
-0.03 |
0.04 |
2022 |
-0.02 |
0.03 |
2021 |
-0.01 |
0.00 |
What is the 52 Week High and Low of Imunon Inc (IMNN)?
The 52-week high and low of Imunon Inc (IMNN) are Rs 6.04 and Rs 1.47 as of 01-Sep-2026.
What is the market cap of Imunon Inc (IMNN)?
Imunon Inc (IMNN) has a market capitalisation of $ 9 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Imunon Inc (IMNN)?
Before investing in Imunon Inc (IMNN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.